Dr. Derek Enlander was born in Belfast, Northern Ireland. He graduated to Medical School at the age of seventeen. He was offered a fellowship to Stanford University Medical School and came originally to the United States for one year. The University extended the fellowship for four years. His research subject was the relationship of Epstein Barr virus to cancer.

He came to New York as Assistant Professor of Medicine at Columbia University and then Associate Director of Nuclear Medicine at New York University (NYU). During a return visit to Belfast, he was asked by a childhood friend (SD) to help him in a then virtually unknown condition, Myalgic Encephalomyelitis (ME). M.E. had caused him to curtail his lucrative real estate practice. This spawned an interest in the disease, which further developed when a patient (JB) introduced him to Kutapressin research in Texas. By then, Dr. Enlander had opened a private practice in Manhattan, and was Physician-in-Waiting to the British Royal Family and to several members of the British government during their visits to New York. Dr Enlander is on the faculty of Mount Sinai Medical School and is an attending physician at Mount Sinai Medical Center New York. He has developed a protocol for the treatment of ME/CFS and Fibromyalgia based on an immune system dysfunction. He has an active research program to which his patients are invited to participate. Ampligen and GcMaf are research treatment programs that are presently being expored

He is presently in private practice in New York and is on the faculty of a major New York Medical School and President of the Israel Medical Research Foundation.